Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

44.96
-0.7200-1.58%
Volume:331.82K
Turnover:14.99M
Market Cap:26.22B
PE:25.24
High:45.68
Open:45.55
Low:44.95
Close:45.68
52wk High:47.86
52wk Low:29.66
Shares:583.17M
Float Shares:379.85M
Volume Ratio:0.77
T/O Rate:0.09%
Dividend:0.88
Dividend Rate:1.96%
EPS(TTM):1.78
EPS(LYR):1.78
ROE:13.20%
ROA:5.15%
PB:4.05
PE(LYR):25.24

Loading ...

BRIEF-Teva And Royalty Pharma Enter Agreement To Accelerate Development Of Potential Treatment For Vitiligo

Reuters
·
Jan 12

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

THOMSON REUTERS
·
Jan 12

Teva - Teva to Share Tev-'408 Trial Results in 2026

THOMSON REUTERS
·
Jan 12

Royalty Pharma - to Provide up to $500 Mln for Teva's Tev-'408

THOMSON REUTERS
·
Jan 12

Royalty Pharma : Tev-'408 Is Currently in Phase 1B for Treatment of Vitiligo and in Phase 2a for Celiac Disease

THOMSON REUTERS
·
Jan 12

Teva and Royalty Pharma Partner in $500 Million Deal to Advance TEV-'408 for Vitiligo

Reuters
·
Jan 12

Assessing Royalty Pharma (RPRX) Valuation After Dividend Increase And Raised Full Year Guidance

Simply Wall St.
·
Jan 10

Royalty Pharma Increases Quarterly Dividend to $0.235 a Share From $0.22, Payable March 10 to Holders of Record on Feb. 20.

MT Newswires Live
·
Jan 09

Royalty Pharma announces $0.235 quarterly dividend

Reuters
·
Jan 09

Royalty Pharma : Dividend of $0.235 per Share Reflects 6.8% Increase in Company's Quarterly Dividend

THOMSON REUTERS
·
Jan 09

Royalty Pharma - Declares Dividend of $0.235 per Share

THOMSON REUTERS
·
Jan 09

Royalty Pharma Files Initial Beneficial Ownership Statement for Arthur Richard McGivern, EVP, Investments & General Counsel

Reuters
·
Jan 07

Royalty Pharma EVP Marshall Urist Reports Sale of Common Shares

Reuters
·
Jan 07

Denali Therapeutics reports $872.9 million cash position ahead of key 2026 milestones

Reuters
·
Jan 06

What's Going On With Royalty Pharma Stock Wednesday?

Benzinga
·
Dec 31, 2025

Royalty Pharma EVP Marshall Urist Reports Sale of Common Shares

Reuters
·
Dec 30, 2025

Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones

THOMSON REUTERS
·
Dec 30, 2025

PTC Therapeutics Sells Remaining Royalty Interest in Evrysdi to Royalty Pharma for $240 Million

Reuters
·
Dec 30, 2025

EVP Marshall Urist Reports Disposal of Royalty Pharma plc Common Shares

Reuters
·
Dec 23, 2025

Royalty Pharma EVP Marshall Urist Reports Sale of Common Shares

Reuters
·
Dec 18, 2025